Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.05Last Year’s EPS
0.96Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 1.72%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted Royalty Pharma's strong financial performance, dynamic capital allocation strategy, and significant portfolio expansions, alongside some concerns about policy uncertainties and ongoing disputes. The company remains optimistic about its future growth and market opportunities.Company Guidance
During Royalty Pharma's first-quarter earnings call for 2025, several key financial metrics and strategic updates were highlighted. Royalty Receipts saw a 12% increase, contributing to a 17% rise in Portfolio Receipts, driven by a strong performance across their diversified portfolio. In terms of capital allocation, the company repurchased $723 million worth of shares, part of a larger $2 billion buyback plan for the year, and deployed over $100 million on royalty transactions. Royalty Pharma also raised its full-year guidance for Portfolio Receipts to a range between $2.975 billion and $3.125 billion, anticipating growth of 6% to 12%. The company reported a strong portfolio cash flow with an adjusted EBITDA margin of about 73%. Additionally, they highlighted several promising developments in their portfolio, including a Phase 3 R&D collaboration with Biogen and positive clinical outcomes for ecopipam in Tourette's syndrome.Strong Financial Performance
Royalty Receipts grew by 12% in the first quarter, reflecting the strength of the diversified portfolio. Portfolio Receipts, including milestone payments, grew by 17% to $839 million.
Dynamic Capital Allocation
Royalty Pharma repurchased $723 million of shares in the first quarter and announced a plan to repurchase up to $2 billion of shares in 2025, while also deploying over $100 million on value-creating royalty transactions.
Portfolio Expansion
Expansion of the development stage pipeline with a Phase 3 R&D funding collaboration with Biogen for litifilimab in lupus, and advancement of trontinemab into Phase 3 in Alzheimer’s disease.
Raised 2025 Financial Guidance
Increased full-year guidance for Portfolio Receipts to $2.975 billion to $3.125 billion, driven by the diversified portfolio's strength and a tailwind from weakening U.S. dollars.
Positive Phase 3 Results for Ecopipam
Reported positive Phase 3 results for ecopipam in Tourette’s syndrome, showing significant benefit and safety, with plans for FDA submission.
RPRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RPRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $32.53 | $32.88 | +1.08% |
Feb 11, 2025 | $31.30 | $31.82 | +1.66% |
Nov 06, 2024 | $26.95 | $26.07 | -3.27% |
Aug 08, 2024 | $26.46 | $25.40 | -4.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Royalty Pharma PLC (RPRX) report earnings?
Royalty Pharma PLC (RPRX) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Royalty Pharma PLC (RPRX) earnings time?
Royalty Pharma PLC (RPRX) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RPRX EPS forecast?
RPRX EPS forecast for the fiscal quarter 2025 (Q2) is 1.05.